Abstract: Provided are methods for detecting membrane derived apoptotic activity. In one embodiment, the present invention provides methods for identifying membrane derived caspase activity. In other embodiments, drug discovery methods are provided for screening compounds that inhibit or enhance membrane derived caspase activity. In the various embodiments, heavy membrane fractions are utilized for the screening methodologies described herein.
Abstract: The invention provides an isolated gene encoding Mch4 or an isolated gene encoding Mch5 as well as functional fragments thereof. Also provided are isolated nucleic acid sequences encoding Mch4 or Mch5 or functional fragment thereof The gene or nucleic acid sequences can be single or double stranded nucleic acids corresponding to coding or non-coding strands of the Mch4 or Mch5 nucleotide sequences. Also provided are genes and nucleic acids encoding functional fragments such as the FADD-like domains Mch4A, Mch4B, Mch5A and Mch5B. Isolated Mch4 or Mch5 polypeptides or functional fragments thereof including the FADD-like domains Mch4A, Mch4B, Mch5A and Mch5B are also provided.
Type:
Grant
Filed:
April 13, 1999
Date of Patent:
September 11, 2001
Assignees:
Thomas Jefferson University, IDUN Pharmaceuticals, Inc.
Inventors:
Emad S. Alnemri, Teresa Fernandes-Alnemri, Gerald Litwack, Robert Armstrong, Kevin Tomaselli
Abstract: The invention provides a single-well, microscale method of determining the specific apoptotic activity of a cell. In the various embodiments, the method comprising contacting a cell population of greater than about 10,000 to 1×106 cells for a time period of between about 30 minutes and 4 hours with a sufficient volume of medium containing an apoptotic specific diagnostic reagent and a diagnostic accessory reagent so as to cover the cell population, and determining the activity of the apoptotic specific diagnostic reagent. The invention also provides a method of identifying a compound which induces apoptosis. The invention further provides a rapid method of identifying a compound which inhibits apoptosis.
Type:
Grant
Filed:
June 5, 1997
Date of Patent:
August 7, 2001
Assignee:
Idun Pharmaceuticals, Inc.
Inventors:
Lawrence C. Fritz, Jose-Luis Diaz, Robert C. Armstrong, Kevin J. Tomaselli
Abstract: The invention provides a single-well, microscale method of determining the specific apoptotic activity of a cell. The method consists of contacting a cell population of about 1×105 cells for a time period of between about 30 minutes and 4 hours with a sufficient volume of medium containing an apoptotic specific diagnostic reagent and a diagnostic accessory reagent so as to cover the cell population, and determining the activity of the apoptotic specific diagnostic reagent. The invention also provides a method of identifying a compound which induces apoptosis. The invention further provides a rapid method of identifying a compound which inhibits apoptosis.
Type:
Grant
Filed:
May 10, 1999
Date of Patent:
June 26, 2001
Assignee:
Idun Pharmaceuticals, Inc.
Inventors:
Lawrence C. Fritz, Jose-Luis Diaz, Robert C. Armstrong, Kevin J. Tomaselli
Abstract: The present invention provides methods for expanding and increasing survival of hematopoietic cell populations, for prolonging viability of an organ for transplantation, and enhancing bioproduction, using interleukin-1&bgr;-converting enzyme (ICE)/CED-3 family inhibitors. Exemplary compounds useful in the methods of the invention are provided herein.
Type:
Grant
Filed:
September 12, 1997
Date of Patent:
March 13, 2001
Assignee:
Idun Pharmaceuticals, Inc.
Inventors:
Lawrence C. Fritz, Kevin J. Tomaselli, Donald S. Karanewski, Steven D. Linton, Xu Bai
Abstract: This invention is directed to novel oxamyl dipeptide ICE/ced-3 family inhibitor compounds. The invention is also directed to pharmaceutical compositions containing these compounds, as well as to the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury, and for the preservation of organs that are to undergo a transplantation procedure.
Type:
Grant
Filed:
October 22, 1998
Date of Patent:
March 6, 2001
Assignee:
Idun Pharmaceuticals, Inc.
Inventors:
Donald S. Karanewsky, Robert J. Ternansky
Abstract: This invention is directed to novel tricyclic ICE/ced-3 family inhibitor compounds. The invention is also directed to pharmaceutical compositions of such tricyclic compounds, plus the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, and for the prevention of ischemic injury.
Abstract: This invention is directed to novel (N-substituted) indole ICE/ced-3-inhibitor compounds. The invention is also directed to pharmaceutical compositions of such indole compounds, plus the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury.
Abstract: The instant methods employs pharmaceutical compositions comprising aromatic azines; and imines, of the Formula 1 to selectively inhibit inflammation by preventing the oxidating burst from phagocytic leukocytes caused by NADPH Oxidase.
Type:
Grant
Filed:
June 5, 1998
Date of Patent:
November 23, 1999
Assignee:
Idun Pharmaceuticals, Inc.
Inventors:
Robert J. Ternansky, Karen L. Valentino, Donald S. Karanewsky
Abstract: This invention is directed to novel tricyclic ICE/ced-3 family inhibitor compounds. The invention is also directed to pharmaceutical compositions of such tricyclic compounds, plus the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, and for the prevention of ischemic injury.
Abstract: The instant methods employs pharmaceutical compositions comprising aromatic azines; and imines, of the Formula 1 to selectively inhibit inflammation by preventing the oxidating burst from phagocytic leukocytes caused by NADPH Oxidase.
Type:
Grant
Filed:
July 8, 1996
Date of Patent:
August 17, 1999
Assignee:
Idun Pharmaceuticals, Inc.
Inventors:
Robert J. Ternansky, Karen L. Valentino, Donald S. Karanewsky
Abstract: This invention is directed to novel (N-substituted)indole ICE-inhibitor compounds. The invention is also directed to pharmaceutical compositions of such indole compounds, plus the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury, and for the preservation of organs that are to undergo a transplantation procedure.
Abstract: The invention provides an isolated gene encoding Mch4 or an isolated gene encoding Mch5 as well as functional fragments thereof. Also provided are isolated nucleic acid sequences encoding Mch4 or Mch5 or functional fragment thereof. The gene or nucleic acid sequences can be single or double stranded nucleic acids corresponding to coding or non-coding strands of the Mch4 or Mch5 nucleotide sequences. Isolated Mch4 or Mch5 polypeptides or functional fragments thereof are also provided.
Type:
Grant
Filed:
March 19, 1996
Date of Patent:
December 22, 1998
Assignee:
IDUN Pharmaceuticals, Inc.
Inventors:
Emad S. Alnemri, Teresa Fernandes-Alnemri, Gerald Litwack, Robert Armstrong, Kevin Tomaselli
Abstract: The invention provides an isolated gene encoding Mch4 or an isolated gene encoding Mch5 as well as functional fragments thereof. Also provided are isolated nucleic acid sequences encoding Mch4 or Mch5 or functional fragment thereof. The gene or nucleic acid sequences can be single or double stranded nucleic acids corresponding to coding or non-coding strands of the Mch4 or Mch5 nucleotide sequences. Also provided are genes and nucleic acids encoding functional fragments such as the FADD-like domains Mch4A, Mch4B, Mch5A and Mch5B. Isolated Mch4 or Mch5 polypeptides or functional fragments thereof including the FADD-like domains Mch4A, Mch4B, Mch5A and Mch5B are also provided.
Type:
Grant
Filed:
June 14, 1996
Date of Patent:
July 28, 1998
Assignee:
Idun Pharmaceuticals, Inc.
Inventors:
Emad S. Alnemri, Teresa Fernandes-Alnemri, Gerald Litwack, Robert Armstrong, Kevin Tomaselli